TickerTalks
Browse all tickers →
TickerTalks›$KARD
KAKARD

Kardigan, Inc.

$KARD·$1.9B·Biotechnology·Healthcare
$20.49+2.6%1Y-6.9%
Mentions · last 7 days
2026-07-29: 0 posts2026-07-30: 0 posts2026-07-31: 0 posts2026-08-01: 0 posts2026-08-02: 0 posts2026-08-03: 3 posts2026-08-04: 0 posts3
Price updated 4h ago·X counts updated 4h ago
KAKARD
$KARDKardigan, Inc.
$20.49+2.60%3 posts
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $KARD, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellStalledAI verdict · as of 2026-08-04

The move has stalled — likely just drifts unless something new shows up.

KARD is a small biotech with no analyst coverage and no 200-day baseline yet — a recent listing where the disclosure is too thin to underwrite either side without off-market diligence.

KARD is a small US-listed biotech vehicle (recent listing or IPO/spinoff) that trades with essentially no institutional research coverage and limited price history.

  • Trading at $19.97 with mid 50M float on 0.37x volume — the profile of a recently-listed biotech where early holders are still working through IPO/deal-related positioning; both entry and exit are practical only in defined windows.
  • No analyst estimates, no fundamentals data, no filings, no news, no sentiment in the bundle — the responsible read is that public disclosure is too thin to build a differentiated view, and any thesis has to lean on off-market diligence.
  • No 200-day baseline nor 52-week-range positioning yet reported, and beta of essentially zero is a math artifact of thin price history — treat all technical signals as unusable until the ticker has more trading history.
  • Bull path requires a next 10-Q or 8-K that establishes an operating base (pipeline milestones, cash runway, any partnership) plus institutional research initiation; bear path is a quiet drift as any early-holder overhang works through, until a specific catalyst appears.
  • With no serious coverage and no operating datapoints, the burden of proof sits on filings and management to appear in the next disclosure cycle.

Skip unless you have primary diligence on the pipeline and management team — the public information here does not support an underwritable thesis yet.

What to watch: Next 10-Q for cash runway and specific pipeline-milestone timelines; any 8-K on clinical readouts or partnership announcements; sell-side research initiation; institutional 13F flow direction; insider transactions; any registration statement suggesting incoming supply.

On the calendar: Next SEC filing (10-Q or 8-K)

thin bundleno newsno sentimentno serious coverage

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment12 posts analyzed · as of 2026-06-25

Kardigan IPO'd on Nasdaq at $16/share raising $400M (13th biopharma IPO of the year), opening at $16.25 with theoretical auction price oscillating $17-18 — clinical-stage precision cardiovascular therapeutics with three programs. $1.8B market cap. Tone is uniformly bullish on the cardio-precision-medicine debut.

Read the AI verdict + X sentiment for $KARD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage cardiovascular company targeting unmet diseases with Danicamtiv (heart failure) and other precision medicines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $KARD.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $KARD

Partial — Clinical-stage cardiovascular company targeting unmet diseases with Danicamtiv (heart failure) and other precision medicines; partial earnings exposure to biotechnology demand dynamics through its product portfolio.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+40.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 26, 2026$-1.43——
Next earningsWed, Sep 2·consensus EPS $-0.68

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.—Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 50.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.005-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 1 other (1 award) in window

See when $KARD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

SC 13DActivist position (5%+)Jun 29SC 13D
AI summary

ARCH Venture Fund XIII LP filed an initial Schedule 13D disclosing a 16.2% stake (15,042,035 shares) in Kardigan Inc. as of June 22, 2026. This new initial 13D indicates a significant new VC investor entering Kardigan; ARCH Venture is known for early-stage life sciences and deeptech investing, signaling institutional interest in this company.

SC 13DActivist position (5%+)Jun 25SC 13D
AI summary

Perceptive Advisors LLC and managing member Joseph Edelman filed a Schedule 13D disclosing an 8.9% stake in Kardigan, Inc., consisting of 8,254,144 shares held across Perceptive Life Sciences Master Fund (2.46M shares) and Perceptive Capital Solutions Holdings LP (5.74M shares), plus 53,483 option shares tied to director Douglas Giordano's board service. The event date was June 18, 2026. Material — a healthcare-focused institutional investor crossing the 5% threshold in a relatively small company with potential influence over strategic direction.

3/ANew insider — initial holdingsJun 243/A
AI summary

HRTG GPE, LLC and affiliated entities filed an amended Form 3/A for Kardigan, Inc. (KARD), triggered by a June 17, 2026 event. HRTG PV, L.P. beneficially owns Series A, B, and B-1 Redeemable Convertible Preferred Stock convertible into approximately 11,741,868 shares of common stock in aggregate, plus warrants (expiring September 2035) to purchase 876,040 shares at $13.42/share. HRTG CIF 2024, L.P. holds Series A preferred convertible into 2,050,166 shares. A 10%+ holder disclosure for a VC/PE-backed company; the convertible preferred and warrants represent meaningful potential dilution upon conversion.

8-KCharter amendmentJun 238-K — Item 5.03: Charter amendment
AI summary

Delaware 001-43354 93-2994203 filed an 8-K on 2026-06-23: reviously disclosed in the Registration Statement on Form S-1, as amended (File No. 333-296236) (the “Registration Statement”), of Kardigan, Inc. (the “Company”), and in connection with the completion of the initial public offering of the Company’s common stock (the “IPO”), the Company filed its third amended and restated certificate of incorporation (the “Amended and Restated Certificate”) with t.

424B4Prospectus supplement (offering)Jun 18424B4
AI summary

Kardigan Inc. (KARD) priced its IPO at $16.00 per share, selling 25,000,000 shares for gross proceeds of $400 million ($372 million net after underwriting discounts). An overallotment option covers an additional 3,750,000 shares. Shares are listed on Nasdaq under 'KARD'; delivery was expected around June 22, 2026. Joint book-running managers are JP Morgan, Jefferies, Leerink Partners, and TD Cowen. Kardigan is a pharmaceutical company (SIC 2834) incorporated in Delaware and headquartered in Princeton, NJ.

3New insider — initial holdingsJun 183
AI summary

Perceptive Advisors LLC filed an initial Form 3 as a 10%-plus beneficial owner of Kardigan Inc. (KARD) in connection with the company's IPO on June 18, 2026. This is a routine large-holder ownership disclosure with no open-market transactions reported.

3New insider — initial holdingsJun 183
AI summary

Brianne Jahn filed an initial Form 3 as an insider of Kardigan Inc. (KARD) in connection with the company's IPO on June 17, 2026. This is a routine insider ownership disclosure with no open-market transactions reported.

3New insider — initial holdingsJun 183
AI summary

Paul L. Berns filed an initial Form 3 as an insider of Kardigan Inc. (KARD) in connection with the company's IPO on June 17, 2026. This is a routine insider ownership disclosure with no open-market transactions reported.

+ 20 other (10 3s · 1 13G · 1 EFFECT · 1 S-1MEF) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Sharesbusinesswire.com·43d agoKardigan rises in Nasdaq debut after upsized $400 million IPOreuters.com·48d agoKardigan Announces Pricing of Upsized Initial Public Offeringbusinesswire.com·48d agoHeart drug developer Kardigan targets $1.4 billion valuation in US IPOreuters.com·55d agoKardigan Begins Process For IPO On Cardiovascular Treatments Promiseseekingalpha.com·64d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$REPL$REGN$IBRX$CAPR$HALO$AURA$ABCL$MRNA
Voices on X · last 7 days

No standout posts about $KARD on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport